Multidrug resistance is frequently characterized by an ATPdependent reduction in cellular drug accumulation. This phenotype can occur in mammalian cells by overexpression of either the multidrug resistance protein (MRP) 1 or P-glycoprotein (MDR1) (1-5). MRP and P-glycoprotein belong to the ATPbinding cassette (ABC) superfamily of transport proteins but share only 15% amino acid identity (1). Nevertheless, both proteins confer resistance to a broad range of cytotoxic xenobiotics including doxorubicin, vincristine, and VP-16 (etoposide), drugs that are widely used in the treatment of many human cancers. However, there is growing evidence that the mechanisms by which MRP and P-glycoprotein reduce cellular drug accumulation are not the same, suggesting that there are major differences in the drug-protein interactions of these two molecules (6 -8).
Multidrug resistance is frequently characterized by an ATPdependent reduction in cellular drug accumulation. This phenotype can occur in mammalian cells by overexpression of either the multidrug resistance protein (MRP) 1 or P-glycoprotein (MDR1) (1) (2) (3) (4) (5) . MRP and P-glycoprotein belong to the ATPbinding cassette (ABC) superfamily of transport proteins but share only 15% amino acid identity (1) . Nevertheless, both proteins confer resistance to a broad range of cytotoxic xenobiotics including doxorubicin, vincristine, and VP-16 (etoposide), drugs that are widely used in the treatment of many human cancers. However, there is growing evidence that the mechanisms by which MRP and P-glycoprotein reduce cellular drug accumulation are not the same, suggesting that there are major differences in the drug-protein interactions of these two molecules (6 -8) .
Like most eukaryotic ABC proteins, MRP and P-glycoprotein contain hydrophobic membrane spanning domains (MSDs) and cytoplasmic nucleotide binding domains (NBDs) (9) . To understand how drugs interact with P-glycoprotein, there has been considerable interest in determining the precise topology of this integral membrane protein. Investigations in most experimental systems support a model in which P-glycoprotein is organized as a symmetrically arranged, tandemly duplicated molecule with each half consisting of six transmembrane segments followed by a NBD (10) , but alternate models have also been proposed (11, 12) .
At present, little is known about the membrane topology of MRP. The topological model we proposed when MRP was cloned in 1992 was based on computer-assisted hydropathy analyses of its deduced amino acid sequence and alignment with the predicted structure of ltpgpA (1) . LtpgpA is an ABC protein cloned from Leishmania tarentolae which was the most closely related protein to MRP known at that time (13) . In the original model, we suggested that MRP consisted of eight transmembrane segments and an NBD in its NH 2 -proximal half and only four transmembrane segments and an NBD in its COOH-proximal half (1) . More recently, alignment of the hydropathy profiles of human MRP with those of its murine ortholog (14) and several members of the ABC superfamily (including the related sulfonylurea receptor, SUR (15) , and the yeast cadmium resistance factor, YCF1 (16) , as well as Pglycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR)) suggested to us a different topology for MRP. In this later model, we predicted that MRP contains two MSDs of six transmembrane helices in a "6 ϩ 6" configuration typical of several eukaryotic ABC transporters (9) , plus an extremely hydrophobic NH 2 -terminal MSD of approximately 220 amino acids (4, 14, 17, 18) . This additional hydrophobic domain is predicted to contain four to six transmembrane segments and is not present in ABC proteins such as P-glycoprotein and CFTR. Thus it is a characteristic feature of members of the MRP branch of the ABC transporter superfamily (4, 14) .
One approach to defining the topology of integral membrane glycoproteins is to identify amino acids that are modified by N-linked oligosaccharides (19, 20) . The co-translational attachment of high mannose oligosaccharides to nascent polypeptide chains occurs on asparagine residues in the sequence Asn-XSer/Thr, where X can be any amino acid except proline (21, 22) . This process is carried out by an oligosaccharyltransferase localized on the lumenal side of the endoplasmic reticulum, so that only asparagine residues that are extracytosolic are glycosylated (23) .
We and others (24, 25) have shown that MRP is N-glycosylated with complex-type oligosaccharides. We have also shown recently that limited proteolysis of MRP cleaves the protein in the region connecting the first NBD (NBD1) and the COOHproximal MSD (MSD3) producing two N-glycosylated fragments. These observations indicated that asparagine residues in both halves of MRP were modified with oligosaccharides (18) . Bakos et al. (26) have used a similar approach to demonstrate that the NH 2 -terminal MSD (MSD1) of MRP is glycosylated. However, which specific N-glycosylation sequons in MSD1 and MSD3 are used and whether the middle MSD (MSD2) is also glycosylated is not known. In the present study, we have carried out more extensive analyses of the partial proteolysis products of MRP together with site-directed mutagenesis of selected asparagine residues to identify the sites of N-linked glycosylation in this protein. The results obtained place constraints on the possible topologies of MRP and indicate that the NH 2 terminus of the protein is localized to the extracellular surface of the plasma membrane.
MATERIALS AND METHODS

Cell Lines and Transfected Cell Populations-SV40-transformed
Cos-1 cells were obtained from the American Type Culture Collection (Rockville, MD). The MRP-overexpressing, multidrug-resistant H69AR small cell lung cancer cell line has been described previously (1) . T14 cells are a HeLa cell population transfected with an episomally replicating pCEBV7 expression construct containing a full-length cDNA encoding human MRP (3) .
Monoclonal Antibodies and Antiserum-Monoclonal antibody (mAb) QCRL-1 is a murine mAb that reacts with the heptapeptide 918 SSYS-GDI 924 in the connector region of MRP (Centocor, Malvern, PA) (18, 27) . MRP-1 is a rabbit polyclonal antiserum raised against a peptide from NBD1 of MRP ( 765 GVNLSGGQKQRVSLA 779 ) (18) and was purified as described (24) . The rat mAb MRPr1 and the mouse mAb MRPm6 were raised against fusion proteins containing MRP amino acids 194 -360 and MRP amino acids 1294 -1430 plus 1497-1531, respectively (28) . Both mAbs were kindly provided by Dr. R. J. Scheper (Free University Hospital, Amsterdam, The Netherlands).
Computer Analyses-The locations of membrane spanning helices in human MRP were predicted using the algorithms of Eisenberg et al. (32) . The topology of MRP was also predicted by the neural network system PredictProtein using a multiple sequence alignment that included human and murine MRP/mrp, human and rabbit multispecific organic anion transporters (MOAT/epithelial basolateral conductance regulator), and yeast YCF1 (33) .
Site-directed Mutagenesis and Generation of MRP Expression Vectors-The assembly of a full-length MRP cDNA in pBluescript II KS ϩ (Stratagene, La Jolla, CA) has been described (2). The full-length cDNA was transferred into pcDNAI/Amp (Invitrogen, San Diego, CA) to generate the pcDNAI-MRP1 expression vector. The asparagine codons of potential N-glycosylation acceptor sites at positions 19, 23, 71, 1006, and 1156 of MRP were converted to glutamine codons by site-directed mutagenesis.
The N23Q and N71Q mutations were generated by a modification of the PCR-based megaprimer method (34) . A template was prepared by cloning the BamHI fragment from pcDNAI-MRP1 (containing the first 840 nucleotides of MRP coding sequence, plus 86 nucleotides of 5Ј-untranslated region and a portion of the pcDNAI/Amp multiple cloning site) into pBluescript SK ϩ in both orientations. The first PCR was carried out on the pBluescript construct containing the BamHI fragment cloned in the EcoRI to HindIII orientation (5Ј 3 3Ј) using the M13 primer and either the N23Q (5Ј-C ACG TGG CAA ACC AGC AAC CCC GAC T-3Ј) or the N71Q (5Ј-A CCT CTC CAG AAA ACC AAA ACT GCC T-3Ј) mutagenic primer (substituted nucleotide positions underlined). The purified PCR product then served as a megaprimer in a second PCR reaction, along with the M13 primer, using the pBluescript construct with the BamHI insert in the HindIII to EcoRI orientation (5Ј 3 3Ј) as a template. The final PCR product was then digested with BamHI and cloned back into pBluescript SK ϩ . The N19Q, N1006Q, and N1156Q mutations were generated using the Transformer TM site-directed mutagenesis kit (CLONTECH Laboratories, Inc., Palo Alto, CA) based on the method developed by Deng and Nickoloff (35) . The templates for mutagenesis were prepared by cloning the BamHI fragment as above (for N19Q) and the XmaI fragment (MRP nucleotides 2337-4322) (for N1006Q and N1156Q) from pcDNAI-MRP1 into pGEM®-3Z (Promega, Madison, WI). Mutagenesis was then performed according to the manufacturer's instructions using the ScaI/ StuI and SspI/EcoRV selection primers (for N19Q and N1006Q/N1156Q mutations, respectively), and the following sense mutagenic oligonucleotide primers: 5Ј-C TGG GAC TGG CAG GTC ACG TGG-3Ј (N19Q), 5Ј-C CCC ATC GTC CAG GGG ACT CAG G-3Ј (N1006Q), and 5Ј-C TAT TCC CAT TTC CAG GAG ACC TTG C-3Ј (N1156Q). The N19Q/N23Q double mutant was also generated by this method using the N19Q mutagenic primer with the N23Q BamHI fragment in pGEM-3Z as a template.
After confirming all mutations by dideoxy sequencing using Sequenase TM version 2.0 (U.S. Biochemical Corp.), DNA fragments containing the desired mutations were transferred back into pcDNAI-MRP1. The N19Q/N23Q/N1006Q triple mutant was prepared by cloning the BamHI fragment containing the N19Q/N23Q mutation into pcDNAI-MRP1/N1006Q. All regions that were synthesized by PCR or by T4 DNA polymerase (when the Transformer TM protocol was used) were confirmed by DNA sequencing of the final constructs.
Transient Expression in Cos-1 Cells-pcDNAI-MRP1 expression vectors encoding wild-type and mutant forms of MRP were transiently transfected into Cos-1 cells using LipofectAMINE (Life Technologies, Inc., Burlington, Ontario, Canada). Briefly, 5 ϫ 10 5 cells per well were seeded in 6-well plates, and 24 h later, cells were washed and overlaid with 1 ml of serum-free Dulbecco's modified Eagle's medium containing 2 g of supercoiled DNA and 8 l of LipofectAMINE. After 4 h, 1 ml of Dulbecco's modified Eagle's medium containing 20% calf serum was added to each well. The medium was replaced after 24 h with 2 ml of fresh Dulbecco's modified Eagle's medium, 10% calf serum, and the cells were incubated for a further 24 -48 h before harvesting.
Deglycosylation and Proteolysis of Membranes-Membrane-enriched fractions were prepared as described previously (27) . Membrane pellets were resuspended in Tris sucrose buffer (250 mM sucrose, 10 mM Tris, pH 7.5), aliquoted, and frozen at Ϫ70°C. After thawing, membranes were disaggregated by passage through a 27-gauge needle. For proteolysis, membrane proteins were diluted to 2-3 g/l in phosphatebuffered saline and incubated at 37°C with diphenylcarbamyl chloridetreated trypsin (ICN Biomedicals, St. Laurent, Quebec, Canada) at trypsin:membrane protein ratios of 1:30 to 1:810 (w:w) for 30 min. Proteolysis was stopped by the addition of phenylmethylsulfonyl fluoride and leupeptin. After centrifugation, membrane pellets were resuspended in phosphate-buffered saline containing 4.8 mM phenylmethylsulfonyl fluoride. In some experiments, membranes were treated with protein N-glycosidase F (PNGase F) (New England Biolabs, Mississauga, Ontario, Canada) (24) . Sodium phosphate, pH 7.5, was added to membrane proteins to a final concentration of 50 mM in the absence of detergents, followed by PNGase F (10 -15 New England Biolabs units/g protein), and the samples were incubated overnight at 37°C.
SDS-Polyacrylamide Gel Electrophoresis and
ImmunoblottingSamples were solubilized and subjected to SDS-polyacrylamide gel electrophoresis essentially as described (2, 24) . Immunoblotting was performed as described (18, 27) , except 4% skim milk powder in TBS-T (10 mM Tris, 0.15 M NaCl, 0.05% Tween 20, pH 7.5) was used as the blocking solution.
RESULTS
The amino acid sequence of MRP contains 14 N-glycosylation sequons (1). Of these, eight are in either NBD1 or NBD2 or in the connector region that joins the two halves of the protein (Fig. 1 ). Previous studies of MRP and other ABC transport proteins indicate that these regions are cytoplasmic (18, 19, 27, 28, 36 ). Predicted Topologies of MRP-Analyses of the MRP sequence using various algorithms for predicting the locations of membrane spanning helices suggested several topological models of MRP (29 -31) . The topology of MSD1 varied according to the algorithm used, with the predicted number of transmembrane segments ranging from four to six (Fig. 1 , left, A-D). As a result, differences in the orientation of the NH 2 terminus and the potential sites of N-glycosylation were also predicted. Models A and D possess six and four transmembrane segments, respectively, and the NH 2 terminus is cytoplasmic. Consequently, Asn 71 is the only potential site of N-glycosylation. In contrast, MSD1 in model B has five transmembrane segments and an extracytoplasmic NH 2 terminus. Accordingly, Asn 19 and Asn 23 are both potential N-glycosylation acceptors and Asn 71 is not. Finally, in model C, the positions of the four predicted transmembrane segments place all three N-glycosylation sequons in the cytosolic NH 2 terminus, where they are inaccessible for glycosylation.
As with MSD1, the predicted topology of MSD2 varied according to the algorithm used. On the basis of previous comparative hydropathy analyses, we and others (4, 9, 14, 26) have proposed that MSD2 possesses six transmembrane segments, a configuration typical of the comparable domain in the P-glycoproteins and many other ABC proteins (Fig. 1, middle) . This topology predicts that Asn 354 in MSD2 is localized to the lumenal or extracellular face of the membrane and is thus a potential site of N-glycosylation.
The predictions of the different algorithms for the topology of MSD3 were more consistent than for MSD1 and MSD2. Two of the models suggest that MSD3 contains six transmembrane segments, as we and others have proposed previously (4, 9, 14, 26) (Fig. 1, right top) . In these models, Asn 1006 is the only potential N-glycosylation acceptor in this domain. In contrast, the other two models predict that MSD3 possesses only four transmembrane segments, as proposed in our original "8 ϩ 4" model of MRP (1) (Fig. 1, right In preliminary experiments, we determined that no proteolytic fragments of MRP were observed after incubation of MRPtransfected HeLa cells with trypsin unless the cells were first permeabilized with digitonin. Since MRP has been shown to be targeted to the plasma membrane in these cells (24) , this indicated that all sites of trypsin digestion we have detected are intracellular (not shown). In subsequent experiments, tryptic digests were carried out on crude membrane preparations. MRP-enriched crude membranes from H69AR cells were digested with trypsin at increasing trypsin to membrane protein ratios up to 1:30 (w:w), and the proteolytic products were detected by immunoblotting (Fig. 2) . Initially, two polypeptides are produced by digestion of a portion of the connector region of MRP. One is a fragment of approximately 120-kDa detected by mAb MRPr1 and MRP-1 antiserum (and to a lesser extent by mAb QCRL-1) which corresponds to the NH 2 -proximal half of MRP (i.e. MSD1 ϩ MSD2 ϩ NBD1) (labeled N-1) (Fig. 2, A-C) . The second is a fragment of 75-80 kDa detected by mAbs QCRL-1 and MRPm6 corresponding to the COOH-proximal half of MRP (i.e. MSD3 ϩ NBD2) (labeled C-1) (Fig. 2, C and D) . We have shown previously that the epitope for mAb QCRL-1 (amino acids 918 -924) lies within the region digested by trypsin, such that this mAb can recognize either fragment depending on whether initial cleavage occurs on the NH 2 -or COOHproximal side of its epitope sequence (18) .
Increased digestion at higher trypsin to membrane protein ratios resulted in cleavage of fragment N-1 and the appearance of a 40 -60-kDa polypeptide that migrates as a broad band detectable with mAb MRPr1 (labeled N-2) ( Fig. 2A) and polypeptides of 57 and 60 kDa detectable with the MRP-1 antiserum (collectively labeled N-3) (Fig. 2B) . Previous studies have shown that the N-2 proteolytic fragment is produced by digestion of a portion of the predicted cytoplasmic region joining MSD1 and MSD2 in fragment N-1 and corresponds to MSD1 (26) . The size and immunoreactivity of the N-3 fragments are consistent with those corresponding to the remainder of fragment N-1 (i.e. MSD2 ϩ NBD1). The sequential appearance of these two N-3 products indicates that the smaller of the fragments is likely produced by trimming of the NH 2 -or COOH-terminal end of the larger fragment. Upon increased digestion, the reactivity of mAb QCRL-1 with the C-1 fragment diminished rapidly, and no smaller products resulting from limited proteolysis of this fragment were detected, consistent with the digestion of the QCRL-1 epitope in the connector region (Fig. 2C) . mAb MRPm6 detected one major proteolytic product of the 75-80-kDa C-1 fragment (labeled C-2) with an apparent molecular mass of 40 kDa (Fig. 2D) .
Glycosylation of Tryptic Fragments of MRP-The glycosylation status of proteolytic fragments of MRP was determined by PNGase F treatment of H69AR membranes after incubation with trypsin. As shown in Fig. 3 (A-C) , the apparent size of fragment N-1 (detected with mAbs MRPr1 and QCRL-1 and MRP-1 antiserum) decreased from 120 to 95 kDa after PNGase F treatment, confirming that this fragment is glycosylated. As previously observed in tunicamycin-treated cells, glycosylation was present in fragment N-2 (corresponding to MSD1) because the size of N-2 shifted from 45-60 to 25 kDa after PNGase F treatment (as detected with mAb MRPr1) (Fig. 3A) (26) . In contrast, no shift in electrophoretic mobility of the N-3 fragments was detected in immunoblots with the MRP-1 antiserum (Fig. 3B) , indicating that the N-glycosylation sequon at Asn 354 in MSD2 of MRP is not used.
The apparent molecular mass of the C-1 fragment (detected with mAbs QCRL-1 and MRPm6) decreased from 75-80 to 58 -60 kDa after PNGase F treatment, confirming that the COOH-proximal half of MRP is glycosylated (Fig. 3, C and D) .
FIG. 2.
Immunoblot analyses of MRP fragments generated by limited proteolysis. MRP-enriched membranes from H69AR cells were digested with trypsin at the indicated trypsin to membrane protein ratios (w/w) for 30 min at 37°C. After reactions were stopped, proteins were separated by SDS-polyacrylamide gel electrophoresis on 5-15% gradient gels and immunoblotted with antibodies known to react with specific regions of MRP (indicated on the box diagram, below), as described under "Materials and Methods." The antibodies used are indicated below the individual blots (A, mAb MRPr1; B, MRP-1 antiserum; C, mAb QCRL-1; D, mAb MRPm6). The designations (N1, N2, N3, C1, and C2) at the side of each blot refer to specific proteolytic fragments described in the text. The approximate limits of these proteolytic fragments are indicated above the box diagram of MRP. Molecular mass markers are indicated in the center of the blots.
FIG. 3. Glycosylation of tryptic fragments of MRP.
MRP-enriched membranes from H69AR cells were digested with trypsin at a 1:50 (w:w) trypsin to membrane protein ratio for 30 min at 37°C. After reactions were stopped, PNGase F was added to half the sample and incubated overnight at 37°C, as described under "Materials and Methods." Samples treated with (ϩ) or without (Ϫ) PNGase F were then subjected to SDS-polyacrylamide gel electrophoresis on 5-15% gradient gels and immunoblotted with MRP site-specific antibodies which are indicated below each blot (A, mAb MRPr1; B, MRP-1 antiserum; C, mAb QCRL-1; D, mAb MRPm6). The designations (N1, N2, N3, C1, and C2) at the side of each blot refer to specific proteolytic fragments described in the text. Molecular mass markers are indicated in the center.
However, the 40-kDa C-2 fragment derived from C-1 (detected with mAb MRPm6) is not glycosylated, because its mobility was unchanged by the same treatment. Because mAb MRPm6 reacts with an epitope near the COOH terminus of the protein, this observation suggested that any sites of N-linked glycosylation in MSD3 were between the NH 2 termini of fragments C-1 and C-2. We have established previously that C-1 results from cleavage in the connector region of MRP at intracellular sites encompassing the mAb QCRL-1 epitope (amino acids 918 -924) (18) . While the exact boundaries of the sites that are cleaved during trypsinolysis are not known, digestion would presumably be limited at the COOH-proximal end of the connector region by the first transmembrane segment of MSD3. This segment is predicted to begin near amino acid 970 in all of our topological models of MRP. If MRP was glycosylated at Asn 1156 , the site in fragment C-1 that is cleaved to produce the C-2 fragment would have to be COOH-proximal to Asn 1156 , resulting in a size difference of more than 186 amino acids (or greater than 20 kDa) between fragments C-1 and C-2 in the PNGase F-treated samples. Consequently, while not formally excluding the possibility of N-glycosylation of Asn 1156 , the location of the glycosylated residue in fragment C-1 within 20 kDa from its NH 2 terminus is most consistent with the utilization of the sequon at Asn 1006 .
Mutagenesis of Potential N-Glycosylation Sites-The limited proteolysis studies conclusively excluded Asn
354 as a site of N-linked glycosylation in MRP, leaving only asparagine residues at positions 19, 23, 71, and 1006 (and possibly 1156) as potential candidates. Accordingly, these asparagines were replaced with glutamine residues singly and in combination by site-directed mutagenesis. Expression vectors encoding the mutant MRP molecules were transiently transfected into Cos-1 cells, and the glycosylation status of the expressed proteins and their proteolytic fragments was determined. Wild-type MRP expressed in these cells migrates as a diffuse band at approximately 190 kDa and co-migrates with wild-type MRP expressed in stably-transfected, drug-resistant HeLa T14 cells (Fig. 4A, lanes 2 and 10) , suggesting that glycosylation of the protein is similar in these two cell types. Wild-type MRP expressed in Cos-1 cells shifts from a broad 190-kDa band to a tight 145-150-kDa band after deglycosylation with PNGase F (Fig. 4A, lane 1) . The apparent size of deglycosylated MRP is less than that predicted from its amino acid sequence (171 kDa). Anomalous electrophoretic mobility of MRP has been observed in certain other cell types (26) and may be the result of excess SDS binding to this relatively hydrophobic protein.
Introduction of the individual N19Q, N23Q, and N71Q mutations in MSD1 did not result in a detectable alteration of the electrophoretic mobility of the intact proteins (Fig. 4A, lanes  3-5) . However, after digestion with trypsin, the N-2 fragments of wild-type MRP and MRP-(N71Q) co-migrated at 43-60 kDa, whereas the N-2 fragments of MRP-(N19Q) and MRP-(N23Q) migrated slightly faster at approximately 38 -50 kDa (Fig. 4B,  lanes 2-5) . The MRP-(N19Q) and MRP-(N23Q) N-2 fragments are glycosylated because they have lower electrophoretic mobility than the deglycosylated 25-kDa N-2 fragment of wildtype MRP (compare with Fig. 4B, lane 1) . These observations indicated that the glycosylation sequons at both Asn 19 and Asn 23 are utilized in wild-type MRP. To confirm that Asn 19 and Asn 23 are the only glycosylated sites in MSD1, we also produced an N19Q/N23Q MRP double mutant. MRP-(N19Q/ N23Q) migrated faster than wild-type MRP and the N19Q, N23Q, and N71Q single mutants (Fig. 4A, compare lane 6 with  lanes 2-5) . The N-2 fragment of the MRP double mutant comigrated with the 25-kDa deglycosylated N-2 fragment of wildtype MRP (Fig. 4B, compare lanes 1 and 6) . These results confirmed that both Asn 19 and Asn 23 , but not Asn
71
, glycosylation sequons in MSD1 of MRP are used.
We next examined expression of the MSD3 glycosylation acceptor site mutants MRP-(N1006Q) and MRP-(N1156Q). The MRP-(N1156Q) mutant co-migrated with the wild-type protein, whereas MRP-(N1006Q) displayed a greater electrophoretic mobility (Fig. 4A, lanes 2, 7 and 8) . The C-1 fragments derived from wild-type MRP and MRP-(N1156Q) also co-migrated, and the C-1 fragment of MRP-(N1006Q) had the same electrophoretic mobility as the PNGaseF-treated wild-type C-1 fragment (Fig. 4C, lanes 1-4) . These observations indicated that FIG. 4 . Immunoblot analysis of site-directed glycosylation mutants of MRP. Asparagine residues at positions 19, 23, 71, 1006, and 1156 of MRP were mutated to glutamine residues singly and in selected combinations by site-directed mutagenesis, and the mutant proteins were transiently expressed in Cos-1 cells. Crude membrane preparations were isolated, and the glycosylation status of the mutant MRP molecules and their tryptic fragments was determined. A, crude membrane proteins from Cos-1 cells expressing wild-type MRP (WT) treated with (ϩ) or without (Ϫ) PNGase F, the single glycosylation site mutant MRP constructs N19Q, N23Q, N71Q, N1006Q, and N1156Q, the double mutant N19Q/N23Q, and the triple mutant N19Q/N23Q/N1006Q were separated by SDS-polyacrylamide gel electrophoresis on 5% gels and immunoblotted with mAb QCRL-1. Crude membranes from MRP-transfected HeLa cells (T14) were included as a control. B and C, samples were digested with trypsin at a 1:50 (w/w) trypsin to membrane protein ratio for 30 min at 37°C. After reactions were stopped, proteins were separated by SDS-polyacrylamide gel electrophoresis on 5-15% gradient gels and immunoblotted with mAb MRPr1 (B) or mAb MRPm6 (C). The designations (N2 and C1) to the right of the blots refer to specific proteolytic fragments described in the text. Molecular mass markers are indicated on the left.
, and Asn 1006 are the only sites of glycosylation in MRP, we constructed a triple mutant in which all three asparagine residues were changed to glutamines. The triple mutant protein ran as a sharp 145-150-kDa band which co-migrated with deglycosylated wild-type MRP (Fig. 4A, compare lanes 1 and 9) . The N-2 and C-1 fragments derived from the triple mutant protein by limited proteolysis co-migrated with the corresponding fragments from PNGase F-treated wild-type MRP (Fig. 4B, lanes 1 and 7, and  Fig. 4C, lanes 1 and 5) . Taken together, our data provide strong evidence that glycosylation at these three sites accounts for all N-linked glycosylation in MRP. DISCUSSION A number of topological models have been proposed for MRP, but direct experimental evidence supporting predicted features of these models is limited to several regions that have been demonstrated by immunological approaches to be localized to the cytoplasm. For example, the identification of the epitope for mAb QCRL-1 confirmed the cytosolic localization of the connector region joining the two halves of MRP (18) . Furthermore, immunostaining of permeabilized cells, but not intact cells, with antisera and mAbs recognizing NBD1 and NBD2 confirmed that these regions are on the cytoplasmic side of the membrane (28) . 2 Finally, the region between MSD1 and MSD2 (which contains the epitope for mAb MRPr1) has also been shown to be cytoplasmic (26, 28) . Identification of extracytosolic regions of MRP has not been possible using an immunological approach because of the lack of suitable antibodies. In the present study, we have taken the alternative approach of identifying the N-glycosylation sequons that are utilized in MRP. Previous limited trypsinolysis studies revealed the presence of two proteolytically hypersensitive regions in MRP, one located in the connector region between NBD1 and MSD3 and the other in the region joining MSD1 and MSD2. These studies also showed that both MSD1 and MSD3 are N-glycosylated (18, 26 When the conservation of the three human MRP N-glycosylation sequons was examined in other eukaryotic ABC transporters, one or two sequons were found within the first 40 amino acids of murine mrp, rat, human, and rabbit MOAT, human and rat SUR, YCF1, and the yeast organic anion resistance gene YOR1/YRS (15, 16, (37) (38) (39) (40) . The sequon at Asn 19 is conserved between human MRP and murine mrp, whereas only the human protein has a sequon at Asn 23 . We have determined that MSD1 of murine mrp expressed in human embryonic kidney cells is N-glycosylated, indicating that Asn 19 is modified in this protein. 2 Peptide sequencing of rat SUR suggests that the NH 2 -proximal glycosylation site at Asn 10 is utilized in this protein (41) . These observations, although limited, suggest that an extracytosolic NH 2 terminus may be a common topological feature unique to proteins within the MRP branch of the ABC superfamily.
In addition to the NH 2 -terminal sequons, all mammalian members of the MRP-related subgroup of ABC proteins have a glycosylation sequon that aligns with Asn 1006 of MRP. Interestingly, this site also aligns with the first of the two N-glycosylation sites in the predicted first extracellular loop of the COOH-proximal half of CFTR (19) . The conservation of both the COOH-proximal and NH 2 -proximal sites suggests that glycosylation of these regions has some functional or regulatory role in this group of mammalian ABC transporters. We have observed that although MRP expressed in Sf21 cells is underglycosylated, it displays transport kinetics similar to those of fully glycosylated MRP (42) . This, together with the observation that MRP in tunicamycin-treated cells retains its ability to reduce drug accumulation, suggests that deglycosylation does not significantly alter the transport properties of MRP (24, 26) . However, glycosylation has been shown to affect the stability and trafficking of a number of different membrane glycoproteins (43, 44) . Further investigations using mammalian cells stably transfected with constructs encoding MRP glycosylation mutants are required to determine whether or not this is also the case for MRP.
The results of the present study are particularly informative with respect to the topology of MSD1 of MRP. We and others (4, 14, 26) have predicted that MSD1 consists of four to six membrane spanning helices. The observed utilization of the glycosylation sequons at Asn 19 and Asn 23 provides the first direct experimental evidence for the localization of the MRP NH 2 terminus on the extracytosolic side of the membrane bilayer. These data, together with the previous demonstration that the loop between MSD1 and MSD2 is cytosolic (26, 28) , place significant constraints on the potential topology of MSD1 and strongly indicate that it contains five membrane spanning segments as is predicted in model B shown in Fig. 1 (left) . This is an unusual topology for an ABC protein, and it appears to be important for MRP function because our structure/function analyses in an Sf21 baculovirus expression system indicate that MSD1 is essential for MRP-mediated leukotriene C 4 transport. 2 In contrast to MSD1, the topologies of MSD2 and MSD3 are less certain. As mentioned previously, we and others (4, 14, 45) have proposed that these domains each contain six transmembrane segments based on comparative hydropathy analyses and sequence alignments of human and mouse MRP/mrp, human and mouse P-glycoproteins, and CFTR. This arrangement for MSD2 places the glycosylation sequon at Asn 354 in an extracytoplasmic location. However, our present findings demonstrate that this sequon is not used. This is not inconsistent with the proposed topology of MSD2 for two reasons. First, the sequence of the Asn 354 acceptor site is not optimal for Nglycosylation since negatively charged amino acids such as aspartic acid at the X position (as is present in the Asn 354 sequon) have been shown to markedly inhibit glycosylation (22) . Second, Asn 354 is located in close proximity to a putative membrane spanning helix. The extracytosolic loop in which Asn 354 is predicted to reside is less than 25 amino acids in length, with Asn 354 situated less than 10 amino acids from a transmembrane segment at the COOH-proximal end of this loop. It has been observed that N-glycosylation is impaired when an acceptor asparagine residue is less than 14 -15 amino acids from the NH 2 -proximal end or 12-14 amino acids from the COOH-proximal end of a transmembrane segment (46) . Furthermore, a comprehensive survey of mammalian polytopic proteins for which there is experimental evidence confirming the utilization of specific glycosylation sites suggests that loops of less than 30 amino acids are likely to be poor candidates for N-glycosylation (47) . Thus, no conclusions about the topology of MSD2 can be inferred from the absence of glycosylation at Asn 354 . Although comparative hydropathy analyses and sequence alignments suggest that MSD3 of MRP, like MSD2, possesses six transmembrane segments (4, 14, 45) , some topological models indicate that MSD3 may have only four transmembrane segments ( Fig. 1) (1) . This configuration does not conform to the widely accepted 6 ϩ 6 model of other mammalian ABC transporters. However, in the region comparable to MSD3 of MRP, an alternative topology of P-glycoprotein with only four transmembrane segments has been suggested by proteolytic and immunological studies in several different expression systems (11, 12, 48) , as well as in drug-selected mammalian cell lines (49) . Whether MRP MSD3 contains four or six transmembrane segments, Asn 1006 is predicted in either case to be extracytoplasmic and thus accessible for glycosylation. Consequently, the identification of Asn 1006 as a site of N-glycosylation does not distinguish between these topologies. On the other hand, it was expected that the MRP-(N1156Q) mutant might be informative because this asparagine residue is predicted to be extracytoplasmic only in the MSD3 configurations with four transmembrane segments. However, the amino acid in the X position of the sequon at Asn 1156 is negatively charged (glutamic acid), making it a poor candidate for N-glycosylation (22) . Thus, as with Asn 354 in MSD2, the absence of glycosylation at Asn 1156 does not provide any information regarding the topology of MSD3.
Finally, we have carried out a prediction of secondary structure using the PredictProtein server to generate a working topological model of MRP on which to base future investigations. Rather than analyzing a single sequence, the PredictProtein server uses a multiple sequence alignment as input for profile-based neural network predictions (33) . In addition to predicting individual helical transmembrane segments, a best model compatible with the neural network output is generated based on the charge difference between extra-and intracytoplasmic regions ("inside positive" rule). Included in our analysis were human MRP and selected related ABC proteins containing an NH 2 -terminal region analogous to MSD1 (murine mrp, human and rabbit MOAT/epithelial basolateral conductance regulator, and YCF1). The human and rat SUR proteins, while relatively closely related to MRP, were excluded from this analysis because their sequences contain additional amino acids that complicate the alignment. Rat MOAT was also excluded to avoid skewing the analysis in favor of predicting the topology of MOAT rather than MRP. As shown in Fig. 5A , the model based upon the PredictProtein analysis has five transmembrane segments in MSD1, with the NH 2 terminus on the extracytosolic side of the membrane, which is consistent with our present experimental data. This model also contains six transmembrane segments in MSD2 and four in MSD3 and correctly places Asn 1006 in MSD3 outside the cell (Fig. 5A ). However, in the absence of direct experimental evidence, we have not ruled out the possibility that MSD3 may have the more conventional ABC transporter configuration with six transmembrane segments (Fig. 5B) (9) . Further investigations are in progress to clarify the topologies of MSD2 and MSD3. Knowledge of the secondary structure of MRP will be important for understanding how drugs and other substrates bind and are transported by this drug resistance protein. 
